AAPL340.86-2.08 (-0.61%) ▼|ABBV289.30+6.62 (+2.34%) ▲|ABT103.44-0.62 (-0.60%) ▼|ACN240.67+3.74 (+1.58%) ▲|ADBE255.12+8.03 (+3.25%) ▲|AMAT405.22-7.89 (-1.91%) ▼|AMD542.38+4.33 (+0.80%) ▲|AMGN433.87+8.93 (+2.10%) ▲|AMT185.39+2.36 (+1.29%) ▲|AMZN263.08+0.63 (+0.24%) ▲|AVGO335.10+0.51 (+0.15%) ▲|AXP320.55+4.14 (+1.31%) ▲|BA189.91-1.51 (-0.79%) ▼|BAC51.03+0.64 (+1.26%) ▲|BKNG163.27+0.67 (+0.41%) ▲|BLK1,135.97+11.37 (+1.01%) ▲|BMY61.36+2.53 (+4.29%) ▲|BNY144.20+1.76 (+1.24%) ▲|BRK-B538.54+6.31 (+1.18%) ▲|C122.41+0.72 (+0.59%) ▲|CAT725.81+0.02 (+0.00%) ▲|CL94.06+1.20 (+1.29%) ▲|CMCSA22.12+0.22 (+1.00%) ▲|COF201.61+1.78 (+0.89%) ▲|COP144.94-0.30 (-0.21%) ▼|COST994.24-1.30 (-0.13%) ▼|CRM239.41-3.05 (-1.26%) ▼|CSCO106.13-0.37 (-0.35%) ▼|CVS94.59+1.91 (+2.06%) ▲|CVX223.53-0.85 (-0.38%) ▼|DE635.15+8.15 (+1.30%) ▲|DHR226.43+2.00 (+0.89%) ▲|DIS111.26+1.67 (+1.52%) ▲|DUK121.12+1.85 (+1.55%) ▲|EMR159.67-0.87 (-0.54%) ▼|FDX300.27+6.49 (+2.21%) ▲|GD343.00+1.57 (+0.46%) ▲|GE297.45-13.84 (-4.44%) ▼|GEV899.53-8.91 (-0.98%) ▼|GILD155.41+2.34 (+1.53%) ▲|GM76.69-6.06 (-7.32%) ▼|GOOG337.70-2.46 (-0.72%) ▼|GOOGL341.56-2.62 (-0.76%) ▼|GS885.62+9.84 (+1.12%) ▲|HD315.71+5.83 (+1.88%) ▲|HON212.83+2.85 (+1.36%) ▲|IBM240.07+3.68 (+1.56%) ▲|INTC93.26+1.23 (+1.33%) ▲|INTU335.41+9.79 (+3.01%) ▲|ISRG436.38+3.20 (+0.74%) ▲|JNJ259.09+5.30 (+2.09%) ▲|JPM336.37+2.84 (+0.85%) ▲|KO92.97-0.45 (-0.48%) ▼|LIN498.89-4.55 (-0.90%) ▼|LLY1,296.20+55.86 (+4.50%) ▲|LMT547.25-0.98 (-0.18%) ▼|LOW198.90+2.98 (+1.52%) ▲|LRCX265.19-7.01 (-2.58%) ▼|MA622.14+5.74 (+0.93%) ▲|MCD246.17+3.50 (+1.44%) ▲|MDLZ63.91+0.57 (+0.90%) ▲|MDT94.29+1.52 (+1.64%) ▲|META690.30-15.14 (-2.15%) ▼|MMM170.09+8.08 (+4.99%) ▲|MO74.99+0.90 (+1.21%) ▲|MRK148.25+4.62 (+3.21%) ▲|MS180.62+2.15 (+1.20%) ▲|MSFT531.69-1.83 (-0.34%) ▼|MU911.34+6.44 (+0.71%) ▲|NEE79.10+0.93 (+1.18%) ▲|NFLX69.71-0.15 (-0.21%) ▼|NKE37.78+0.57 (+1.53%) ▲|NOW148.42+3.06 (+2.11%) ▲|NVDA217.03-0.06 (-0.03%) ▼|ORCL132.33+2.74 (+2.11%) ▲|PEP134.05+0.48 (+0.36%) ▲|PFE30.13+0.69 (+2.34%) ▲|PG158.51+0.82 (+0.52%) ▲|PLTR194.61+0.46 (+0.24%) ▲|PM201.31+0.26 (+0.13%) ▲|QCOM175.35+1.82 (+1.05%) ▲|RTX190.27-1.84 (-0.96%) ▼|SBUX99.54+1.67 (+1.71%) ▲|SCHW90.78+1.20 (+1.34%) ▲|SO90.75+1.48 (+1.66%) ▲|SPG205.75+3.26 (+1.61%) ▲|T23.51+0.31 (+1.31%) ▲|TMO687.69+8.31 (+1.22%) ▲|TMUS158.51+2.42 (+1.55%) ▲|TSLA373.79+5.73 (+1.56%) ▲|TXN279.73+3.58 (+1.30%) ▲|UBER68.69-1.27 (-1.82%) ▼|UNH421.26+14.38 (+3.53%) ▲|UNP287.20+0.19 (+0.06%) ▲|UPS98.73+1.27 (+1.30%) ▲|USB58.83+0.98 (+1.69%) ▲|V407.05+4.13 (+1.03%) ▲|VZ44.52+0.37 (+0.84%) ▲|WFC81.91+0.11 (+0.13%) ▲|WMT118.18-0.52 (-0.44%) ▼|XOM176.57-1.71 (-0.96%) ▼|AAPL340.86-2.08 (-0.61%) ▼|ABBV289.30+6.62 (+2.34%) ▲|ABT103.44-0.62 (-0.60%) ▼|ACN240.67+3.74 (+1.58%) ▲|ADBE255.12+8.03 (+3.25%) ▲|AMAT405.22-7.89 (-1.91%) ▼|AMD542.38+4.33 (+0.80%) ▲|AMGN433.87+8.93 (+2.10%) ▲|AMT185.39+2.36 (+1.29%) ▲|AMZN263.08+0.63 (+0.24%) ▲|AVGO335.10+0.51 (+0.15%) ▲|AXP320.55+4.14 (+1.31%) ▲|BA189.91-1.51 (-0.79%) ▼|BAC51.03+0.64 (+1.26%) ▲|BKNG163.27+0.67 (+0.41%) ▲|BLK1,135.97+11.37 (+1.01%) ▲|BMY61.36+2.53 (+4.29%) ▲|BNY144.20+1.76 (+1.24%) ▲|BRK-B538.54+6.31 (+1.18%) ▲|C122.41+0.72 (+0.59%) ▲|CAT725.81+0.02 (+0.00%) ▲|CL94.06+1.20 (+1.29%) ▲|CMCSA22.12+0.22 (+1.00%) ▲|COF201.61+1.78 (+0.89%) ▲|COP144.94-0.30 (-0.21%) ▼|COST994.24-1.30 (-0.13%) ▼|CRM239.41-3.05 (-1.26%) ▼|CSCO106.13-0.37 (-0.35%) ▼|CVS94.59+1.91 (+2.06%) ▲|CVX223.53-0.85 (-0.38%) ▼|DE635.15+8.15 (+1.30%) ▲|DHR226.43+2.00 (+0.89%) ▲|DIS111.26+1.67 (+1.52%) ▲|DUK121.12+1.85 (+1.55%) ▲|EMR159.67-0.87 (-0.54%) ▼|FDX300.27+6.49 (+2.21%) ▲|GD343.00+1.57 (+0.46%) ▲|GE297.45-13.84 (-4.44%) ▼|GEV899.53-8.91 (-0.98%) ▼|GILD155.41+2.34 (+1.53%) ▲|GM76.69-6.06 (-7.32%) ▼|GOOG337.70-2.46 (-0.72%) ▼|GOOGL341.56-2.62 (-0.76%) ▼|GS885.62+9.84 (+1.12%) ▲|HD315.71+5.83 (+1.88%) ▲|HON212.83+2.85 (+1.36%) ▲|IBM240.07+3.68 (+1.56%) ▲|INTC93.26+1.23 (+1.33%) ▲|INTU335.41+9.79 (+3.01%) ▲|ISRG436.38+3.20 (+0.74%) ▲|JNJ259.09+5.30 (+2.09%) ▲|JPM336.37+2.84 (+0.85%) ▲|KO92.97-0.45 (-0.48%) ▼|LIN498.89-4.55 (-0.90%) ▼|LLY1,296.20+55.86 (+4.50%) ▲|LMT547.25-0.98 (-0.18%) ▼|LOW198.90+2.98 (+1.52%) ▲|LRCX265.19-7.01 (-2.58%) ▼|MA622.14+5.74 (+0.93%) ▲|MCD246.17+3.50 (+1.44%) ▲|MDLZ63.91+0.57 (+0.90%) ▲|MDT94.29+1.52 (+1.64%) ▲|META690.30-15.14 (-2.15%) ▼|MMM170.09+8.08 (+4.99%) ▲|MO74.99+0.90 (+1.21%) ▲|MRK148.25+4.62 (+3.21%) ▲|MS180.62+2.15 (+1.20%) ▲|MSFT531.69-1.83 (-0.34%) ▼|MU911.34+6.44 (+0.71%) ▲|NEE79.10+0.93 (+1.18%) ▲|NFLX69.71-0.15 (-0.21%) ▼|NKE37.78+0.57 (+1.53%) ▲|NOW148.42+3.06 (+2.11%) ▲|NVDA217.03-0.06 (-0.03%) ▼|ORCL132.33+2.74 (+2.11%) ▲|PEP134.05+0.48 (+0.36%) ▲|PFE30.13+0.69 (+2.34%) ▲|PG158.51+0.82 (+0.52%) ▲|PLTR194.61+0.46 (+0.24%) ▲|PM201.31+0.26 (+0.13%) ▲|QCOM175.35+1.82 (+1.05%) ▲|RTX190.27-1.84 (-0.96%) ▼|SBUX99.54+1.67 (+1.71%) ▲|SCHW90.78+1.20 (+1.34%) ▲|SO90.75+1.48 (+1.66%) ▲|SPG205.75+3.26 (+1.61%) ▲|T23.51+0.31 (+1.31%) ▲|TMO687.69+8.31 (+1.22%) ▲|TMUS158.51+2.42 (+1.55%) ▲|TSLA373.79+5.73 (+1.56%) ▲|TXN279.73+3.58 (+1.30%) ▲|UBER68.69-1.27 (-1.82%) ▼|UNH421.26+14.38 (+3.53%) ▲|UNP287.20+0.19 (+0.06%) ▲|UPS98.73+1.27 (+1.30%) ▲|USB58.83+0.98 (+1.69%) ▲|V407.05+4.13 (+1.03%) ▲|VZ44.52+0.37 (+0.84%) ▲|WFC81.91+0.11 (+0.13%) ▲|WMT118.18-0.52 (-0.44%) ▼|XOM176.57-1.71 (-0.96%) ▼|
17.9 C
New York
Tuesday, October 20, 2026

Tag: trial

newsFORsourcecompanycontentinformation1releasesmarket

Find Mining Launches One-Stop AI Cloud Mining for Sustainable Digital Wealth

As Bitcoin returns to the $100,000 mark and global demand for clean energy and remote computing services continues to grow, Find Mining, a long-established cloud mining platform founded in 2018, announced that it has officially launched a new one-stop multi-currency AI cloud mining solution and supporting mobile applications, committed to providing global users with a smarter, low-threshold, and sustainable way to increase the value of digital assets. 
As Bitcoin returns to the $100,000 mark and global demand for clean energy and remote computing services continues to grow, Find Mining, a long-established cloud mining platform founded in 2018, announced that it has officially launched a new one-stop multi-currency AI cloud mining solution and supporting mobile applications, committed to providing global users with a smarter, low-threshold, and sustainable way to increase the value of digital assets.

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...

GPRC5D-directed Therapies Market is Anticipated to Gain Momentum During the Forecast Period (2025-2034) Owing to Unmet Need in Multiple Myeloma | DelveInsight

The GPRC5D-directed therapies market is witnessing robust growth, driven by the high unmet need in relapsed/refractory multiple myeloma. Innovative modalities like CAR-T cells, bispecific...

BioLab Holdings, Inc. Launches Multicenter Clinical Trial to Evaluate Amnion Grafts for Chronic Wounds

Study Will Assess Real-World Effectiveness of Tri-Layer and Single-Layer Amnion Grafts in Treating Diabetic Foot and Venous Leg Ulcers PHOENIX, July 3, 2025...

Contact Levi & Korsinsky by August 11, 2025 Deadline to Join Class Action Against Rocket Pharmaceuticals, Inc. (RCKT)

NEW YORK, July 03, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Brain Defender Enters 2025 Cognitive Wellness Spotlight as Demand for Transparent, Non-Stimulant Support Surges

As consumers turn to ingredient-based mental clarity tools, Brain Defender emphasizes formulation transparency and non-clinical support in the evolving cognitive wellness space. 
As consumers turn to ingredient-based mental clarity tools, Brain Defender emphasizes formulation transparency and non-clinical support in the evolving cognitive wellness space.

Quebec implements public reimbursement of Pluvicto® – a defining milestone for radioligand therapy in Canada

Pluvicto® now publicly funded in provinces covering most Canadians, offering renewed hope to those facing progressive PSMA-positive metastatic castration-resistant prostate cancer Momentum builds nationwide as...

Clearmind Medicine Announces IRB Approval for Phase 1/2a Clinical Trial for Alcohol Use Disorder at Tel Aviv Sourasky Medical Center

Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received Institutional Review Board (IRB) approval from Tel Aviv Sourasky Medical Center (TASMC) in Tel Aviv, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This approval will enable patient enrollment at TASMC, a leading clinical site in Israel, prior to commencing this first-in-human trial at the site.

BioAtla Presents Data from Ongoing Dose Escalation of BA3182, Dual-Conditionally Binding EpCAM x CD3 Bispecific T-cell Engager, in Patients with Treatment Refractory Metastatic Adenocarcinoma...

Adverse events were generally low-grade, transient, and readily manageable

ZINFI Tops G2 Summer 2025 PRM Grid with Highest Customer Satisfaction Score

ZINFI Again Named a G2 Leader in Partner Relationship Management for Summer 2025, Achieving Highest Satisfaction Rating in the Industry PLEASANTON, Calif., July 3, 2025...

Advancing Bone Health: European Commission Approves Biocon Biologics’ Denosumab Biosimilars

BENGALURU, India, July 3, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd., today announced that...

Novotech Earns Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services

Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech sets the global standard in contract research for biotechs...

Novotech Earns Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services

Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech sets the global standard in contract research for biotechs...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTrial

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers